NHS England plans a phased rollout of tirzepatide to treat severe obesity, with early trials showing significant weight loss. Digital clinics and multidisciplinary teams will deliver the drug to 240,000 people initially. read more
Read Also
- Novo Nordisk's Options: A Look at What the Big Money is Thinking
- Stock Of The Day: FedEx Delivers An Important Trading Lesson
- Nasdaq Gains Over 100 Points; Beneficient Shares Spike Higher
- Could Paramount Gain Additional NFL Content Through Skydance Merger? New Report Indicates ESPN Talks Stalled
- Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
- Stellantis In Hot Water: Analyst Downgrades Stock Due To Downward Pricing Pressure And Inventory Issues
- Energy Sector Rebound: 3 Stocks Poised for Strong Gains
- New Drill Results from Alaska Project Positive
- Wall Street Rallies, Small Caps Outperform On Strong Jobs Report, Chinese Stocks Soar To 32-Month Highs: What's Driving Markets Friday?
- Analyst updates AMD stock price forecast ahead of AI event
Latest Benzinga
- Novo Nordisk's Options: A Look at What the Big Money is Thinking
- Stock Of The Day: FedEx Delivers An Important Trading Lesson
- Nasdaq Gains Over 100 Points; Beneficient Shares Spike Higher
- Could Paramount Gain Additional NFL Content Through Skydance Merger? New Report Indicates ESPN Talks Stalled
- Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
- Stellantis In Hot Water: Analyst Downgrades Stock Due To Downward Pricing Pressure And Inventory Issues
- Energy Sector Rebound: 3 Stocks Poised for Strong Gains
- New Drill Results from Alaska Project Positive
- Wall Street Rallies, Small Caps Outperform On Strong Jobs Report, Chinese Stocks Soar To 32-Month Highs: What's Driving Markets Friday?
- Breaking Down Axsome Therapeutics: 19 Analysts Share Their Views